In phase 2 trials Aura Biosciences’ virus-like drug conjugate (VDC) infrared light-activated AU-011 therapy successfully bound to and killed tumour cells.
Presenting the data at ARVO, A/Prof Amy Schefler from Houston’s Weill Cornell Medical College, said, “With recent advances in treatments for metastatic cancer, patients are living longer and the incidence of choroidal metastases from breast and lung cancer dramatically impact patients’ vision and their overall quality of life. AU-011 has the potential to offer a new, vision preserving targeted therapy.”
